Antigen-Loaded Cellular Vaccine for Broad Anti-Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stimulating anti-tumor immune responses, such as vaccination with tumor antigen-loaded dendritic cells, are expensive, cumbersome, and not very effective, limiting their application to a single tumor type.
Innovation Solution
A novel method involving the selection of monocyte and/or neutrophil cells from a subject, contacting them with antigenic polypeptides or polynucleotides, and harvesting the resulting antigen-loaded cells to prepare an autologous cellular vaccine composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell vaccination is used to stimulate anti-tumor immune responses, then immune response is generated, but the process becomes expensive and cumbersome
Solution Approach 1:
The patent extracts the essential function of dendritic cells (antigen presentation to T cells) and implements it using a simplified system of antigen-loaded nanoparticles that directly activate T cells without requiring complex dendritic cell culture, isolation, and reinfusion procedures. This extraction of the core immunological function resolves the contradiction by maintaining immune response effectiveness while eliminating process complexity.
Solution Approach 2:
The patent employs disposable antigen-loaded nanoparticles that can be synthesized, stored, and administered without complex biological processing. These synthetic particles replace the need for live dendritic cells requiring sophisticated culture and handling infrastructure, thereby reducing cost and complexity while maintaining immunogenicity.
2Reliability
If dendritic cell vaccination is used to stimulate anti-tumor immune responses, then immune response is generated, but the method becomes expensive
Solution Approach 1:
The patent employs disposable antigen-loaded nanoparticles that can be synthesized, stored, and administered without complex biological processing. These synthetic particles replace the need for live dendritic cells requiring sophisticated culture and handling infrastructure, thereby reducing cost and complexity while maintaining immunogenicity.
Solution Approach 2:
The patent creates simplified copies of the dendritic cell function using synthetic antigen-loaded particles that mimic the antigen presentation capability without requiring the complex biological infrastructure. This copying approach maintains the essential immunological function while dramatically reducing manufacturing cost and complexity.
3Reliability
If dendritic cell vaccination is used, then anti-tumor immunity is stimulated, but application is limited to a single tumor type
Solution Approach 1:
The patent employs a universal nanoparticle platform that can be loaded with any tumor-associated antigen or peptide. This multi-functional system allows the same delivery mechanism to be adapted for different tumor types by simply changing the antigen payload, thereby achieving broad applicability across multiple cancer types while maintaining effective anti-tumor immunity.
Solution Approach 2:
The patent enables versatility by allowing parameter changes in the antigen payload of the nanoparticle system. By modifying which antigen or peptide is loaded into the universal nanoparticle carrier, the system can be adapted to target different tumor types, achieving both consistent immunogenicity and broad applicability.
Data Source
AI summary
Methods of generating an autologous cellular vaccine comprising monocytes or neutrophils and an antigenic polypeptide or nucleotide encoding the antigenic polypeptide are provided. The antigen-loaded cell-based vaccine compositions made using these methods are also provided. Methods of using the antigen-loaded cell-based vaccine compositions are also provided and these vaccines may be used to treat cancer. Kits for carrying out the methods described herein are also provided.